Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00338-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsmi=287993264&_hsenc=p2ANqtz--6-mukSsDrIfkEFuexi0lRCoxEE0NGOfbMSMfV-aNvkuWIftuk6z7-isPBFE2jZJiuzUAavbroTV8vWUVFD2AcGVfE_A&utm_content=287993264&utm_source=hs_email